Bladder bowel dysfunction in children with Down's syndrome

Nikita R Bhatt1, Louise Murchison2, George Yardy3

  • 1Department of Urology, Ipswich Hospital, East Suffolk and North Essex NHS Foundation Trust (ESNEFT), Heath Rd, Ipswich, IP4 5PD, UK. nikitarb89@gmail.com.

Insights

Bladder Bowel Dysfunction (BBD) is common in Down's Syndrome (DS) and often requires surgery. Early identification and management are crucial for protecting the renal tract in these patients.

Area of Science:

  • Pediatric Urology
  • Genetics
  • Gastroenterology

Background:

  • Bladder Bowel Dysfunction (BBD) is a recognized condition in individuals with Down's Syndrome (DS).
  • Understanding the specific challenges faced by DS patients with BBD is essential for effective care.

Purpose of the Study:

  • To determine the incidence, demographics, presentation, complications, and bladder management strategies in Down's Syndrome patients experiencing Bladder Bowel Dysfunction.
  • To consolidate the largest available cohort of BBD cases in DS patients.

Main Methods:

  • A systematic review adhering to PRISMA guidelines was conducted.
  • Searches were performed on MEDLINE and SCOPUS using specific keywords related to Down's Syndrome and voiding dysfunction.
  • A case series from two pediatric urology centers was incorporated.

Main Results:

  • The study included 38 patients with BBD and DS, with a mean age of 12 years and a 2:1 male:female ratio.
  • Common presentations included functional constipation (90%), recurrent urinary tract infections (38%), and enuresis (56%).
  • Over 56% of patients required surgical intervention, with medical and behavioral treatments showing limited success.

Conclusions:

  • BBD is prevalent in DS patients and can lead to severe complications necessitating surgical intervention.
  • Standard interventions are often unreliable due to poor patient compliance.
  • Early identification and management are vital for renal tract protection; regular screening for urogenital anomalies in DS is recommended.
Abstract

Related Concept Videos

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation01:30

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation

Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
656
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
524
The Micturition Reflex01:26

The Micturition Reflex

Urination, or micturition involves the coordination of the bladder's detrusor muscle and two sphincters to ensure controlled bladder emptying.
The process begins with bladder filling, where the bladder wall stretches as urine accumulates. This stretching activates the urine storage reflex, mediated by the sacral spinal segments and the pontine storage center. Efferent sympathetic impulses stimulate the detrusor muscle to relax and the internal urethral sphincter to contract, facilitating...
2.2K
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
594
Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
825
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
689